Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2308336 | 0.89 | PKM (0.31) | — | |
| SCHEMBL336077 | 0.82 | OR51E2 (0.50) | OR51E2FKBP5CRBN | |
| SCHEMBL88947 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL3838535 | 0.80 | — | — | |
| Trifluoroacetic Acid SCHEMBL419508 | 0.79 | — | — | |
| Trifluoroacetic Acid SCHEMBL3566248 | 0.79 | OR51E2 (0.62) | OR51E2FKBP5CRBNTDP1 | |
| Trifluoroacetic Acid SCHEMBL29566076 | 0.77 | CRBN (0.64) | OR51E2FKBP5CRBNTDP1 | |
| Trifluoroacetic Acid SCHEMBL15355467 | 0.77 | TSHR (0.37) | TDP1HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL29139510 | 0.76 | UHRF1 (0.34) | — | |
| Caprolactam SCHEMBL5422431 | 0.76 | CRBN (0.61) | OR51E2FKBP5CRBNTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621189-B | Lactam derivative and application thereof | 上海拓界生物医药科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-114621189-A | Lactam derivative and application thereof | 上海拓界生物医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-2512246-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8735417-B2 | Aminopyrimidines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120309735-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-06 | — | — | US | disclosed |
| EP-2512246-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075560-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309735-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | OR51E2 3066/4885FKBP5 3465/4885CRBN 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.